MDT

100.01

+0.25%↑

A

146.96

+0.77%↑

VEEV

244.4

+2.32%↑

HQY

97.41

-0.3%↓

PHR.US

16.95

-3.09%↓

MDT

100.01

+0.25%↑

A

146.96

+0.77%↑

VEEV

244.4

+2.32%↑

HQY

97.41

-0.3%↓

PHR.US

16.95

-3.09%↓

MDT

100.01

+0.25%↑

A

146.96

+0.77%↑

VEEV

244.4

+2.32%↑

HQY

97.41

-0.3%↓

PHR.US

16.95

-3.09%↓

MDT

100.01

+0.25%↑

A

146.96

+0.77%↑

VEEV

244.4

+2.32%↑

HQY

97.41

-0.3%↓

PHR.US

16.95

-3.09%↓

MDT

100.01

+0.25%↑

A

146.96

+0.77%↑

VEEV

244.4

+2.32%↑

HQY

97.41

-0.3%↓

PHR.US

16.95

-3.09%↓

Search

Quidel Corp

Open

32.97 2.71

Overview

Share price change

24h

Current

Min

31.75

Max

33.5

Key metrics

By Trading Economics

Employees

6,600

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-20.59% downside

Dividends

By Dow Jones

Next Earnings

11 Feb 2026

Market Stats

By TradingEconomics

Market Cap

114M

1.7B

Previous open

30.26

Previous close

32.97

Quidel Corp Chart

Past performance is not a reliable indicator of future results.

Related News

7 Jan 2026, 23:11 UTC

Earnings

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

7 Jan 2026, 22:55 UTC

Major Market Movers

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

7 Jan 2026, 21:39 UTC

Major Market Movers

Raytheon Down Following Trump Post Criticizing Company

7 Jan 2026, 20:13 UTC

Major Market Movers

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

7 Jan 2026, 20:03 UTC

Major Market Movers

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

7 Jan 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 Jan 2026, 23:46 UTC

Market Talk

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

7 Jan 2026, 23:42 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

7 Jan 2026, 23:34 UTC

Market Talk

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

7 Jan 2026, 23:29 UTC

Acquisitions, Mergers, Takeovers

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

7 Jan 2026, 22:48 UTC

Market Talk

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

7 Jan 2026, 22:46 UTC

Earnings

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

7 Jan 2026, 22:45 UTC

Earnings

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

7 Jan 2026, 22:43 UTC

Acquisitions, Mergers, Takeovers

Revolution Medicines Draws Takeover Interest -- 2nd Update

7 Jan 2026, 22:42 UTC

Earnings

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

7 Jan 2026, 22:41 UTC

Earnings

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

7 Jan 2026, 22:41 UTC

Earnings

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

7 Jan 2026, 22:40 UTC

Major Market Movers

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

7 Jan 2026, 22:31 UTC

Market Talk

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

7 Jan 2026, 22:22 UTC

Market Talk

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

7 Jan 2026, 22:01 UTC

Market Talk

Valuations of New Zealand Property Stocks Supportive -- Market Talk

7 Jan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 Jan 2026, 21:46 UTC

Market Talk

Northern Star's Revised Guidance Looks Achievable -- Market Talk

7 Jan 2026, 21:22 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

7 Jan 2026, 21:18 UTC

Acquisitions, Mergers, Takeovers

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

7 Jan 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

7 Jan 2026, 20:29 UTC

Acquisitions, Mergers, Takeovers

AbbVie Near Deal for Revolution Medicines -- Update

7 Jan 2026, 20:27 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

7 Jan 2026, 19:58 UTC

Market Talk

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

7 Jan 2026, 19:48 UTC

Major Market Movers

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Peer Comparison

Price change

Quidel Corp Forecast

Price Target

By TipRanks

-20.59% downside

12 Months Forecast

Average 26.5 USD  -20.59%

High 31 USD

Low 22 USD

Based on 5 Wall Street analysts offering 12 month price targets forQuidel Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

1

Buy

3

Hold

1

Sell

Financials

$

About Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat